{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:58:12Z","timestamp":1776704292446,"version":"3.51.2"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbamcr.2026.120125","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:58:05Z","timestamp":1771358285000},"page":"120125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["FBXO32 activates the PI3K\/AKT pathway by inhibiting PTEN through ubiquitination of TAL1 in hepatocellular carcinoma"],"prefix":"10.1016","volume":"1873","author":[{"given":"Yujie","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120125_bb0015","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/HEP.0000000000000572","article-title":"The rapidly evolving landscape of HCC: selecting the optimal systemic therapy","volume":"81","author":"Zanuso","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120125_bb0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","article-title":"Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers","volume":"42","author":"Wang","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbamcr.2026.120125_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.115683","article-title":"Harnessing function of EMT in hepatocellular carcinoma: from biological view to nanotechnological standpoint","volume":"227","author":"Alqurashi","year":"2023","journal-title":"Environ. Res."},{"key":"10.1016\/j.bbamcr.2026.120125_bb0030","doi-asserted-by":"crossref","first-page":"0144","DOI":"10.34133\/bmef.0144","article-title":"Revisiting treatment strategies: addressing epithelial-to-mesenchymal transition-induced resistance in hepatocellular carcinoma","volume":"6","author":"Naserkhaki","year":"2025","journal-title":"BME Front."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/s12967-025-06592-2","article-title":"Ubiquitination in hepatocellular carcinoma immunity","volume":"23","author":"Zhao","year":"2025","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120125_bb0040","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.7150\/thno.42735","article-title":"F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects","volume":"10","author":"Tekcham","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120125_bb0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41417-024-00861-w","article-title":"FBXO22 promotes HCC angiogenesis and metastasis via RPS5\/AKT\/HIF-1alpha\/VEGF-A signaling axis","volume":"32","author":"Lei","year":"2025","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120125_bb0050","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02644-1","article-title":"FBXO32 ubiquitination of SUFU promotes progression and lenvatinib resistance in hepatocellular carcinoma via hedgehog signaling","volume":"42","author":"Wang","year":"2025","journal-title":"Med. Oncol."},{"issue":"15","key":"10.1016\/j.bbamcr.2026.120125_bb0055","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2016-12-754051","article-title":"SCL\/TAL1: a multifaceted regulator from blood development to disease","volume":"129","author":"Porcher","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120125_bb0060","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2019.08.164","article-title":"TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN\/PI3K\/AKT pathway","volume":"519","author":"Wu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbamcr.2026.120125_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1378386","article-title":"The underlying mechanism and targeted therapy strategy of miRNAs cross-regulating EMT process through multiple signaling pathways in hepatocellular carcinoma","volume":"11","author":"Chen","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120125_bb0070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.32604\/or.2023.029549","article-title":"Zyxin promotes hepatocellular carcinoma progression via the activation of AKT\/mTOR signaling pathway","volume":"31","author":"Cai","year":"2023","journal-title":"Oncol. Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s11658-025-00733-7","article-title":"YY1 induced USP13 transcriptional activation drives the malignant progression of hepatocellular carcinoma by deubiquitinating WWP1","volume":"30","author":"Zhu","year":"2025","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120125_bb0080","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41388-022-02212-1","article-title":"DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6","volume":"41","author":"Zhang","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0085","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13046-020-01768-8","article-title":"Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis","volume":"39","author":"Wu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s13046-022-02531-x","article-title":"Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-kappaBp65\/HK2 signalling","volume":"41","author":"Chen","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120125_bb0095","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/15548627.2021.2007027","article-title":"CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma","volume":"18","author":"Yao","year":"2022","journal-title":"Autophagy"},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120125_bb0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12032-024-02411-8","article-title":"Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma","volume":"41","author":"Miao","year":"2024","journal-title":"Med. Oncol."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120125_bb0105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00432-024-05948-3","article-title":"FBXO family genes promotes hepatocellular carcinoma via ubiquitination of p53","volume":"150","author":"Gong","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120125_bb0110","article-title":"Comprehensive analysis of expression, prognostic value, and immune infiltration for ubiquitination-related FBXOs in pancreatic ductal adenocarcinoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.bbamcr.2026.120125_bb0115","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/0008-5472.CAN-23-3638","article-title":"FBXO32 stimulates protein synthesis to drive pancreatic cancer progression and metastasis","volume":"84","author":"Su","year":"2024","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120125_bb0120","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41418-020-00710-x","article-title":"FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells","volume":"28","author":"Habel","year":"2021","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0125","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-017-01366-x","article-title":"FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development","volume":"8","author":"Sahu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2026.120125_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111824","article-title":"New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities","volume":"141","author":"Ashrafizadeh","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbamcr.2026.120125_bb0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2023.10.001","article-title":"Transcriptional regulation of EMT transcription factors in cancer","volume":"97","author":"Saitoh","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120125_bb0140","first-page":"842","article-title":"The FBXO32\/ATR\/ATM axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression","volume":"55","author":"Lu","year":"2023","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120125_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06635-4","article-title":"FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120125_bb0150","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1074\/jbc.M704981200","article-title":"Ubiquitination and degradation of Tal1\/SCL are induced by notch signaling and depend on Skp2 and CHIP","volume":"283","author":"Nie","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120125_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002175","article-title":"Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth","volume":"21","author":"Sharma","year":"2023","journal-title":"PLoS Biol."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120125_bb0160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ijc.35315","article-title":"Neo-enhancers in T-cell acute lymphoblastic Leukaemia (T-ALL) and beyond","volume":"158","author":"Smith","year":"2026","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120125_bb0165","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2017.328","article-title":"Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system","volume":"32","author":"Bornschein","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120125_bb0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41392-022-01290-7","article-title":"TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN","volume":"8","author":"Qiu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120125_bb0175","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.3324\/haematol.2021.279718","article-title":"TAL1 cooperates with PI3K\/AKT pathway activation in T-cell acute lymphoblastic leukemia","volume":"107","author":"Thielemans","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120125_bb0180","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14728222.2019.1685501","article-title":"RAS\/RAF\/MEK\/ERK, PI3K\/PTEN\/AKT\/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma","volume":"23","author":"Akula","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120125_bb0185","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/hep.30307","article-title":"PI3Kdelta is a therapeutic target in hepatocellular carcinoma","volume":"68","author":"Ko","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120125_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.120043","article-title":"ESCO2 drives breast cancer proliferation and metastasis through PI3K\/AKT\/mTOR phosphorylation: a potential therapeutic target","volume":"1872","author":"Li","year":"2025","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120125_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119916","article-title":"Hypoxia reduces SLC27A5 to promote hepatocellular carcinoma proliferation by repressing HNF4A","volume":"1872","author":"Tao","year":"2025","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926000212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926000212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:06:54Z","timestamp":1776701214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488926000212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0167488926000212"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120125","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FBXO32 activates the PI3K\/AKT pathway by inhibiting PTEN through ubiquitination of TAL1 in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120125"}}